Copeptin as a diagnostic PH marker in acute pulmonary embolism

Year 2022, , 1040 - 1045, 30.12.2022

Necmi Baykan , Şule Yakar , Seda Özkan , Ahmet Şen , Ömer Salt , Polat Durukan

https://doi.org/10.33808/clinexphealthsci.1054109

Abstract

Objective: The present study aimed to investigate the effectiveness of copeptin levels in detecting increased pulmonary artery pressure and right ventricular dysfunction in patients with acute pulmonary embolism.
Methods: A total of 116 patients who presented to the emergency department with chest pain or dyspnea and were diagnosed with acute pulmonary embolism and 30 healthy controls were included in the study. Plasma copeptin levels of patients and healthy control group were measured. Right ventricular functions and pulmonary artery pressures were evaluated in echocardiography of patients diagnosed with acute
pulmonary embolism.
Results: Copeptin levels were significantly higher in patients with right ventricular dysfunction than in those without right ventricular dysfunction [median 1.06(0.03–7.14) vs. 0.59(0.31–2.50), p= 0.01].
Conclusion: Copeptin can be used as a new biomarker in the diagnosis of acute pulmonary embolism and in predicting right ventricular dysfunction and increased pulmonary artery pressure in patients with acute pulmonary embolism

Keywords

Pulmonary embolism, mortality, pulmonary wedge pressure, right ventricular dysfunction

References

• [1] İpekci A. Pulmonary Embolism. Phnx Med J 2019;1(1):51-63.
• [2] Ozturk N, Baygutalp NK, Bayramoglu A, Polat H, Gul MA, Bakan E, Aslan S, Gunes ON. The evaluation of serum copeptin levels and some commonly seen thrombophilic mutation prevalence in acute pulmonary embolism. Biochemical Genetics 2016;54(3):306-312.
• [3] Kalkan AK, Ozturk D, Erturk M, Kalkan ME, Cakmak HA, Oner E, Uzun F, Tasbulak O, Yakisan T, Celik A. The diagnostic value of serum copeptin levels in an acute pulmonary embolism. Cardiology Journal 2016;23(1):42-50.
• [4] Volpi S, Rabadan-Diehl C, Aguilera G. Vasopressinergic regulation of the hypothalamic pituitary adrenal axis and stress adaptation. Stress 2004;7:75–83.
• [5] Bolignano D, Cabassi A, Fiaccadori E, Ghigo E, Pasquali R, Peracino A, Peri A, Plebani M, Santoro A, Settanni F, Zoccali C. Copeptin (CTproAVP), a new tool for understanding the role of vasopressin in pathophysiology. Clin Chem Lab Med 2014;52(10):1447–1456.
• [6] Katan M, Christ-Crain M. The stress hormone copeptin: a new prognostic biomarker in acute illness. Swiss Med Wkly 2010;140(24):11–15.
• [7] Katan M, Morgenthaler N, Widmer I, Puder JJ, Konig C, Muller B, Christ-Crain M. Copeptin, a stable peptide derived from the vasopressin precursor, correlates with the individual stress level. Neuro Endocrinol Lett 2008;29:341–346.
• [8] Wyzgał A, Koc M, Pacho S, Bielecki M, Wawrzyniak R, Kostrubiec M, Ciurzynski M, Kurnicka K, Goliszek S, Paczynska M, Palczewski P, Pruszczyk P. Plasma copeptin for short term risk stratification in acute pulmonary embolism. Journal of Thrombosis and Thrombolysis 2016;41(4):563-568.
• [9] Nickel NP, Lichtinghagen R, Golpon H, Olsson KM, Brand K, Welte T, Hoeper MM. Circulating levels of copeptin predict outcome in patients with pulmonary arterial hypertension. Respiratory Research 2013;14(1):130.
• [10] Vuilleumier N, Simona A, Méan M, Limacher A, Lescuyer P, Gerstel E, Bounameaux H, Aujesky D, Righini M. Comparison of cardiac and non-cardiac biomarkers for risk stratification in elderly patients with non-massive pulmonary embolism. PloS One 2016;11(5).
• [11] Khan SQ, Dhillon OS, O’Brien RJ, StruckJ, Quinn PA, Morgenthaler NG, Squire IB, Davies JE, Bergmann A, Ng LL. C-terminal provasopressin (copeptin) as a novelandprognostic marker in acutemyocardialinfarction: LeicesterAcuteMyocardialInfarctionPeptide (LAMP) study. Circulation 2007;115:21.
• [12] Treschan TA, Peters J. The vasopressin system: Physiology and clinical strategies. Anesthesiology 2006;105:599–612.
• [13] Morgenthaler NG, Struck J, Alonso C, Bergmann A. Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem 2006;52:112–119.
• [14] Timuralp B. Pulmoner tromboembolide kardiyovasküler sistemde gelişen patofizyolojik değişiklikler. Metintaş M (editör). Pulmoner Tromboemboli. ASD Toraks yayınları, Metin Ofset Matbaacılık, Eskişehir 2001:73-83. (Turkish)
• [15] Coşkun B, Kırkıl G, Hamdi M, Yıldız M, Özbay Y. Submasif pulmoner tromboemboli olgularında sağ ventrikül disfonksiyonunu saptamada beyin natriüretik peptid ve kardiyak troponin I’nın tanı değeri. Turk Toraks Derg 2012;13:163-168. (Turkish)
• [16] Goldhaber SZ. Cardiac biomarkers in pulmonary embolism. Chest 2003;123:82-84.
• [17] Goldsmith SR, Gheorghiade M. Vasopressin antagonism in heart failure. J Am Coll Cardiol. 2005;46:1785–1791.
• [18] Deveci F, Öner Ö, Telo S, Kırkıl G, Balin M, Kuluöztürk M. Prognostic value of copeptin in patients with acute pulmonary thromboembolism. The Clinical Respiratory Journal 2019;13(10):630-636.
• [19] Laporte S, Mismetti P, Décousus H, Uresandi F, Otero R, Lobo JL, Monreal M. Clinical predictors for fatal pulmonary embolism in 15,520 patients with venous thromboembolism: findings from the Registro Informatizado de la Enfermedad Trombo Embolica venosa (RIETE) registry. Circulation 2008;117:1711– 1716.
• [20] Aujesky D, Jiménez D, Mor MK, Geng M, Fine MJ, Ibrahim SA. Weekend versus week day admission and mortality afteracu tepulmonary embolism. Circulation 2009;119:962–968